Fol. Biol. 2020, 66, 117-122
https://doi.org/10.14712/fb2020066040117
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population
References
1. 2012) Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One, 7, e36046.
< , T., Ibegbu, C. C., Kalokhe, A. S., Yu, T., Ray, S. M., Rengarajan, J. (https://doi.org/10.1371/journal.pone.0036046>
2. 2011) Programmed death ligand 1 is expressed by non–Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 17, 4232-4244.
< , D. J., Yamada, R. E., Said, J., Pinkus, G. S., Betting, D. J., Timmerman, J. M. (https://doi.org/10.1158/1078-0432.CCR-10-2660>
3. 2013) The PD-1/PDL1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98, 953-963.
< , D., Serra, S., Coscia, M., Rossi, D., D’Arena, G., Laurenti, L., Jaksic, O., Fedele, G., Inghirami, G., Gaidano, G., Malavasi, F., Deaglio, S., Deaglio, S. (https://doi.org/10.3324/haematol.2012.077537>
4. 2017) Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J. Geriatr. Oncol. 8, 229-235.
< , R., Karantanos, T., Sira, E., Hartshorn, K. L. (https://doi.org/10.1016/j.jgo.2017.02.001>
5. 2018) Aging, immune senescence and immunotherapy: a comprehensive review. Semin. Oncol. 45, 187-200.
< , R., Hartshorn, K., Rahma, O., Lin, N., Snyder-Cappione, J. E. (https://doi.org/10.1053/j.seminoncol.2018.08.006>
6. 2010) The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219-242.
< , L. M., Sage, P. T., Sharpe, A. H. (https://doi.org/10.1111/j.1600-065X.2010.00923.x>
7. 2015) PD-L1 and PD1 expression in lymphomas. Blood 126, 3899-3899.
< , Z., Bilalovic, N., Vranic, S., Arguello, D., Reddy, S., Ghosh, N. (https://doi.org/10.1182/blood.V126.23.3899.3899>
8. 2012) Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 7, e35178.
< , M., Zaleska, J., Mertens, D., Tomczak, W., Wlasiuk, P., Kosior, K., Piechnik, A., Bojarska-Junak, A., Dmoszynska, A., Giannopoulos, K. (https://doi.org/10.1371/journal.pone.0035178>
9. 2015) The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leuk. Lymphoma 56, 2908-2913.
< , M., Karabon, L., Karczmarczyk, A., Zajac, M., Skorka, K., Zaleska, J., Wlasiuk, P., Chocholska, S., Tomczak, W., Bojarska-Junak, A., Dmoszynska, A., Frydecka, Giannopoulos, K. (https://doi.org/10.3109/10428194.2015.1017820>
10. 2019) Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leuk. Lymphoma 60, 2498-2507.
< , B. K., Wheeler, E., Hornbuckle, K., Shana’ah, A. Y., Youssef, Y., Smith, L., Hassan Ii, Q., Klamer, B., Zhang, X., Long, M., Baiocchi, R.A., Maddocks, K., Johnson, A.J., Byrd, J.C., Alinari, L. (https://doi.org/10.1080/10428194.2019.1569231>
11. 2011) Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350, 17-37.
, H. T., Ahmed, R., Okazaki, T. (
12. 2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986-2010.
< , T., Flores-Montero, J., van der Velden, V. H., Martin- Ayuso, M., Bottcher, S., Ritgen, M., EuroFlow Consortium. (https://doi.org/10.1038/leu.2012.122>
13. 2019) Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int. J. Mol. Sci. 20,
< , P. (https://doi.org/10.3390/ijms20184417>
14. 2016) Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum. Pathol. 54, 17-24.
< , T., Bodmer-Haecki, A., Dirnhofer, S., Tzankov, A. (https://doi.org/10.1016/j.humpath.2016.03.005>
15. 2007) Cartography of gene expression in CD8 single cells: novel CCR7- subsets suggest differentiation independent of CD45RA expression. Blood 109, 2863-2870.
< , M., Evaristo, C., Legrand, A., Nicoletti, A., Rocha, B. (https://doi.org/10.1182/blood-2006-06-027060>
16. 2010) Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis. Markers 29, 47-53.
< , S., Hoeller, S., Willi, N., Dirnhofera, S., Tzankov, A. (https://doi.org/10.1155/2010/404069>
17. 2012) Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin. Cancer Res. 18, 678-687.
< , C., Wong, R., Mason, M., Fegan, C., Man, S., Pepper, C. (https://doi.org/10.1158/1078-0432.CCR-11-2630>
18. 2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121, 1612-1621.
< , J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G, Gribben, J. G. (https://doi.org/10.1182/blood-2012-09-457531>
19. 2009) PD-1+ memory phenotype CD4+ T cells expressing C/EBPα underlie T cell immunodepression in senescence and leukemia. Proc. Natl. Acad. Sci. USA 106, 15807-15812.
< , K., Nakashima, Y., Hattori, M., Hamazaki, Y., Minato, N. (https://doi.org/10.1073/pnas.0908805106>
20. 2016) PD-L1 status in refractory lymphomas. PLoS One 11, e0166266.
< , S., Ghosh, N., Kimbrough, J., Bilalovic, N., Bender, R., Arguello, D., Veloso, Y., Dizdarevic, A., Gatalica, Z. (https://doi.org/10.1371/journal.pone.0166266>
21. 2013) Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98, 1458-1466.
< , L., Qian, J., Lu, Y., Li, H., Bao, H., He, D., Liu, Z., Zheng, Y., He, J., Li, Y., Neelapu, S., Yang, J., Kwak, L.W., Yi, Q., Cai, Z. (https://doi.org/10.3324/haematol.2012.071340>
22. 2008) Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and Bcell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum. Pathol. 39, 1050-1058.
< , L., Chetaille, B., Serriari, N., Attias, C., Guillaume, Y., Arnoulet, C., Olive, D. (https://doi.org/10.1016/j.humpath.2007.11.012>
23. 2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131, 68-83.
< , Z. Y., Zhou, J., Young, K. H. (https://doi.org/10.1182/blood-2017-07-740993>
24. 2019) Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol. Lett. 17, 3382-3386.
, J., Hu, G. (